Abstract: The present invention relates to the use of a biopolymer for reducing the formation of a biofilm, preferably on a substrate, whereby the biopolymer is preferably a polypeptide, such as recombinant spider silk polypeptide. The present invention further relates to methods for producing a substrate which reduces the formation of a biofilm on a surface of said substrate.

Abstract: Provided are self-adhering cleaning compositions that may include (a) an adhesion promoter, (b) a glycine betaine ester, and (c) water. Commonly, the adhesion promoter may include at least one compound including one or more polyalkoxy groups and the glycine betaine ester may be a compound of formula (I): Me3N+—CH2—C(O)—O—R X? (I) wherein R is an aliphatic group having 8 to 22 carbon atoms and X? represents an inorganic or organic anion. Typically, the composition is a gel and may have a gel melt temperature of about 55-80° C., a viscosity at 25° C. of at least about 150,000 cP, and/or a hardness of at least about 150 g. Methods for treating a hard surface, such as a toilet bowl, using the self-adhering cleaning compositions are also provided.

Abstract: A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.

Abstract: This disclosure features elongated prosthetic devices that can be used to repair, e.g., resurface or occlude, a defect of a semicircular canal, e.g., a superior semicircular canal dehiscence, as well as methods of making and using these devices. For example, the devices can be made using three-dimensional (3D) printing.

Abstract: Hybrid amphiphilic star copolymer nano micelles are prepared in the invention. Cage shaped octa(?-aminopropyl) silsesquioxanes is selected as the inorganic part, and L-glutamic benzyl ester—five membered ring anhydride is ring-opening polymerized by the initiation of amino groups on the surface of cage shaped octa(?-aminopropyl) silsesquioxanes, producing copolymers with cage shaped octa(?-aminopropyl) silsesquioxanes as nucleus and poly (L-glutamic-benzyl ester) as arms. The copolymers reacts with monomethoxy poly (ethylene glycol) carboxylic acid by condensation. Finally, the benzyl groups in the side chains of poly (L-glutamic acid-benzyl ester) are converted into hydrazine groups by acylhydrazination to obtain hybrid amphiphilic star copolymer nano micelles. The micelles can load doxorubicin, they are safe to human body and have good application prospects.

Abstract: Provided is an anticancer compound including a cleavable linker specifically activated in a tumor microenvironment, and use thereof. The anticancer compound is represented by the following formula, wherein, R1 is a normal functional group or a protection group; R2 is Ala, Thr, Val or Ile; R3 is Ala, Val or Asn; R4 is a drug group linked via a hydroxyl group or an amino group; and the general formula of the drug is R4H. The anticancer compound is only activated at a local portion of a tumor, thus avoiding the defect of immune system damage of a traditional chemotherapeutic drug, and promoting tumor immunization by removing a tumor immunosuppression cell. The anticancer compound or pharmaceutical composition thereof is jointly used with immunotherapy, thus improving the effect of treating the tumor, and effectively inhibiting tumor metastasis and osseous metastasis.

Abstract: A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient. Also provided are compositions and kits finding use in practicing embodiments of the methods.

Abstract: Aspects of the subject disclosure may include, for example, a method including receiving from a first network slice comprising a first set of virtual network functions instantiated in a network, a first request to chain the first network slice to a second network slice comprising a second set of virtual network functions instantiated in the network to cooperatively facilitate providing a service to a first communication device, transmitting a second request to the first network slice to route a portion of user plane communication traffic associated with the first communication device to the second network slice, and transmitting a third request to the second network slice to receive the portion of the user plane communication traffic associated with the first communication device from the first network slice and to cooperatively facilitate providing a service to the first communication device via the first network slice and the second network slice. Other embodiments are disclosed.

Abstract: A method for manufacturing a hyaluronan conjugate comprises providing hyaluronan in solution or gel form, reacting the hyaluronan in solution or gel form with anhydride reagent to provide a hyaluronan hemi-ester with a chain of length L between the hyaluronan and the ester group, and subsequently binding the hyaluronan hemi-ester to a pharmaceutically active compound. A hyaluronan conjugate comprises hyaluronan having free hemi-ester-groups and a pharmaceutically active compound bound to the hyaluronan via hemi-ester groups, wherein the hemi-ester groups have a chain length of 2-9 atoms. The hyaluronan conjugate is suitable for use in various methods of treatment in human or veterinary medicine and for preparation of a medicament for use in human or veterinary medicine.

Abstract: This invention relates to microgel compositions, and in particular, to gel compositions formed by binding a plurality of individual microgel particles together. The present invention also relates to processes for the preparation of these compositions and their use for particular applications, especially medical applications such as the repair of damaged, degenerated or inappropriately formed load-bearing tissue (such as, for example, intervertebral discs).

Abstract: The invention comprises a ready to use film dosage form comprising microemulsion of an Active Pharmaceutical Ingredient embedded or immobilized in a thin polymeric matrix as a double microemulsion and a process of making the same. The microemulsion in the film dosage form of this invention is capable of being absorbed through mucosal route. The process of making the film dosage of this invention comprises steps of forming a film forming dispersion containing film forming polymers, excipients and microemulsion of active pharmaceutical ingredient, casting the same in the form of a film and drying the cast of the film being carried out by means of drying conditions that suit to retain stability of the active pharmaceutical ingredient being selected such that drying of the film is achieved retaining the moisture trapped in the microemulsion embedded in the polymeric film.

Abstract: In one aspect, apparatuses for providing chemical gradients are described herein. In some embodiments, an apparatus described herein comprises a conduit having a first end and a second end, one or more microchannels disposed in the conduit and extending from the first end toward the second end, and a fiber coiled around the exterior of at least one microchannel, wherein the fiber comprises an active agent that is operable to diffuse into the interior of the microchannel.

Abstract: It is an object of the present invention to provide a method for preparing a water extract of ashwagandha, which comprises increasing the amounts of withanone and withaferin A contained as active ingredients in the water extract of ashwagandha leaves. In addition, it is another object of the present invention to more economically and simply provide a pharmaceutical composition comprising ashwagandha leaves. The present invention relates to a method for preparing a water extract of ashwagandha leaves, which comprises extracting ashwagandha leaves with water in the presence of cyclodextrin, and a method for enhancing the anticancer activity of the water extract of ashwagandha leaves. The present invention also relates to a pharmaceutical composition for treating or preventing cancer, comprising the water extract of ashwagandha leaves. The present invention further relates to a pharmaceutical composition comprising dry powders of ashwagandha leaves and cyclodextrin.

Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates material that is useful in culturing and transferring cells as well as delivering cells. The material comprises plant derived cellulose nanofibers or derivatives thereof, wherein the cellulose nanofibers are in a form of a hydrogel or membrane. The invention also provides methods for producing these materials and compositions and uses thereof.

Abstract: The present invention provides methods for inhibition of human herpes virus replication in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a cardiac glycoside analog, including for example, a digitoxin analog and pharmaceutically acceptable carrier. Other methods of the present invention include administering a digitoxin analog along with at least one other biologically active compound and pharmaceutically acceptable carrier. Methods for inhibition of the ?3 subtype of the Na/K ATPase in a subject comprising administering to the subject a therapeutically effective amount of a pharmaceutically acceptable composition comprising a digitoxin analog are also provided.

Abstract: A quantification of a particular element comprised in magnetic particles enclosed in a volume involves applying a first time-varying magnetic field to the volume, having a first magnitude and a first frequency and applying a second time varying magnetic field, not parallel with the first magnetic field for causing precession of the magnetized particles. The second magnetic field is an RF field having a second frequency equal to the Larmor-frequency of the particular element. Thereafter the resultant magnetization originating from the volume and modulated by the time-varying field is measured, and at least one frequency component of the resultant magnetization is determined. A power and/or voltage of the at least one frequency component is calculated and a quantity of the magnetic particles enclosed in the volume is determined based thereon.

Abstract: The present invention relates to a method for lyophilizing a composition for multiple target nucleic acid sequence amplification reaction and a lyophilizate prepared by the method. The present method is very effective in lyophilizing a composition containing a high concentration of oligonucleotides. The lyophilizates prepared by the present invention exhibits excellent properties in terms of both sensitivity and specificity, equivalent performance capacity to conventional liquid formulation and furthermore remarkable storage stability. Accordingly, the lyophilizates prepared by the present invention would be very useful in diagnosis.

Abstract: The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.

Abstract: Surface conjugated diamagnetic Chemical Exchange Saturation Transfer (diaCEST) agent carriers and methods of making and using are described herein. The particles are safe alternatives to conventional paramagnetic or superparamagnetic metal-based MRI contrast agents that are often toxic and therefore not biocompatible. The carriers described herein can provide simultaneous monitoring of multiple particle types labeled with ‘multicolor’ diaCEST contrast agents. In some embodiments, the carriers are micro- and/or nanoparticles. In other embodiments, the carriers are liposomes. In some embodiments, the particles and/or liposomes are mucus penetrating. In other embodiments, the particles and/or liposomes are not mucus penetrating.

Abstract: The invention relates to an anhydrous cosmetic or dermatological formulation comprising a viscose lipid-containing preparation and propellant gas consisting essentially of one or more substances selected from hydrofluorocarbons, n-butane, isobutane and propane. The formulation permits application to the skin by spraying of an otherwise nonsprayable preparation. The formulation is free from readily volatile solvents, surfactants, and preferably free from silicones.

Abstract: Simulated tissue products and methods involving an enhanced simulated tissue product, the enhanced simulated tissue product formed from a polyvinyl alcohol material having a molecular chain length in a range of at least approximately 7000 vinyl alcohol repeat units; and water, wherein the polyvinyl alcohol material has a preferred molecular chain length in a range of at least approximately 7150 vinyl alcohol repeat units; wherein the aqueous polyvinyl alcohol solution involves an additive, and, wherein the additive involves a plurality of nanoparticles. The simulated tissue products and methods are further useful with multi-metric surgery simulator devices, systems, and methods, such as those for training surgical tasks.

Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.

Abstract: A non-aqueous electrolyte secondary battery has a positive electrode having a positive electrode active material layer, a negative electrode having a negative electrode active material layer, and an electrolyte layer having an electrolyte solution containing a non-aqueous solvent. At least one of the positive electrode active material layer and the negative electrode active material layer contains an electrode material for a non-aqueous electrolyte secondary battery having a core part including an electrode active material and a shell part including a conductive material in a base material formed by a gel-forming polymer having a liquid absorption rate with respect to the electrolyte solution of 10 to 200%.

Abstract: A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan; and an additive selected from the group consisting of a hydration promoter, a particle adhesion inhibitor, a particle aggregation inhibitor, and combinations thereof. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

Abstract: The invention relates to a composition in the form of an injectable aqueous solution, of which the pH is from 6.0 to 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analog; b) a co-polyamino acid bearing carboxylate charges and hydrophobic radicals Hy, said co-polyamino acid consisting of glutamic or aspartic units and said hydrophobic radicals Hy having the following formula I: *GpRrGpAaGpC)p ??I characterized in that the composition does not comprise a basal insulin of which the isoelectric point pI is from 5.8 to 8.5. It also relates to a composition characterized in that it moreover comprises a prandial insulin.

Abstract: A system and method for evaluating wound healing dressings, treatments, and other variables. The present invention includes in vitro systems and methods for testing wound dressing materials for bacterial control, moisture control, and surface contact properties. The present invention further includes in vivo systems and methods for testing wound dressings, treatments, and other variables utilizing arrays of wound wells on an experimental subject animal. Wound arrays allow for different wound healing variables to be tested with numerous experimental trials within the same subject animal, giving reliable results and reducing the number of subject animals required for testing.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.

Abstract: Methods, devices, and medicaments that include a drug are provided for use in the treatment of the prostate by locally administering the drug into the bladder of a patient to achieve a sustained concentration of the drug in urine in the bladder sufficient to produce a therapeutic concentration of the drug in the prostate. The drug may be delivered into the bladder from an intravesical drug delivery device inserted into the bladder, wherein the device continuously releases the drug into the urine in the bladder over an extended period of hours or days.

Abstract: A novel charge-shifting copolymer is provided comprising a first charge-shifting monomer that is cationic under physiological conditions and which possesses cationic groups that may be converted into anionic groups under physiological conditions, a second monomer comprising at least one primary amine that is not convertible to an anionic group under physiological conditions, and optionally, one or more monomers which are polar uncharged monomers. A hydrogel system incorporating this copolymer, as well as a capsule system, are also provided.

Abstract: An object of the present invention is to provide an analyte-measuring sensor using a thermoresponsive polymer, which is a novel analyte-measuring sensor capable of quantitatively measuring a target analyte with higher sensitivity. The analyte-measuring sensor of the present invention comprises a labeled particle capable of specifically reacting with a measurement target analyte, a thermoresponsive polymer, a charged substance exhibiting a positive or negative zeta potential in a solution, and a metal particle, and said metal particle is coated with a copolymer of said labeled particle, said charged substance and said thermoresponsive polymer.

Abstract: Articles having metal, metalloid or non-metal surfaces containing an antimicrobial layer comprising antimicrobial oligomers or polymers are suitable for use in medical devices, sanitary surfaces and other applications. Antimicrobial layers contain an organophosphorus layer deposited on an article surface and antimicrobial oligomers or polymers bonded to the organophosphorus layer.

Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be injected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.

Abstract: Disclosed are a targeting aptamer for atherosclerosis and a preparation method and application thereof. The targeting aptamer is a targeting aptamer fragment for atherosclerosis obtained through screening of macrophage-derived foam cells together with reverse screening of smooth muscle cells, endothelial cells, and THP-1 cells using a SELEX method; and the use of the targeting aptamer in preparation of an MRI targeting nano-contrast agent for atherosclerosis allows the specific binding of the MRI targeting nano-contrast agent for atherosclerosis only with the macrophage-derived foam cells, and allows high specific binding thereof with vascular tissues with AS lesion, this improving targeting effect of the MRI targeting nano-contrast agent for atherosclerosis and realizing early specific diagnosis of arterial sclerosis.

Abstract: A composition for use in a nasal application, the composition including an aqueous carrier and a viscosity agent. The viscosity agent is in the range of about 4% to about 15% by weight. The viscosity agent is in solution with the aqueous carrier. The solution of the aqueous carrier and the viscosity agent is configured as a thixotropic composition.

Abstract: A nitric oxide gas-releasing conduit configured for surgical implantation through a patient's tympanic membrane. The nitric oxide gas-releasing conduit comprises a gas-permeable cured resin material configured for releasably sequestering therein gas. The gas-permeable cured resin material is charged with nitric oxide gas. The nitric oxide gas-releasing conduit may be optionally coated with an antimicrobial gas-releasing composition. The gas-releasing coating composition may be configured to release nitric oxide.

Abstract: Embodiments herein include coated medical devices and coatings with salt groups. In an embodiment, a coated medical device is included, the coated medical device including a substrate and a polymeric layer disposed over the substrate. The polymeric layer includes a polymer and has an exterior surface. The coated medical device further includes a plurality of salt groups bonded to the polymer of the polymeric layer and disposed on the exterior surface of the polymeric layer. The salt groups can be the reaction product of a reactive group with an acid or base. In an embodiment, a method of making a medical device is included. Other embodiments are also included herein.

Abstract: A composition in the form of an injectable aqueous solution, the pH of which is between 6.0 and 8.0, including at least (a) a basal insulin, the isoelectric point pI of which is between 5.8 and 8.5; and (b) a co-polyamino acid bearing carboxylate charges and substituted with hydrophobic radicals. In one embodiment, the compositions also include a prandial insulin and/or a gut hormone.

Abstract: Provided herein are a biocompatible hemostatic product and a tissue sealant, including polyethylene oxide particles with a viscosity-average molecular weight ranging from 100,000 to 7,000,000 Daltons, a particle size ranging from 0.5 ?m to 2000 ?m and a water absorbency capacity ranging from 1 to 500 times of its own weight. Also provided herein is a method for preparing biocompatible hemostatic product and tissue sealant and the use of the biocompatible hemostatic product and tissue sealant in hemostasis, preventing adhesion, avoiding infection, promoting tissue healing, and sealing wound of tissues and organs either on animal's body surface, or inside body's cavity.

Abstract: An antimicrobial polymer for use in an ophthalmic implant, includes at least one antimicrobial monomer; and at least one other monomer selected from an acrylic, silicone, vinyl and collagen monomer.

Abstract: A plasma-activated coating (PAC) process covalently binds enzymes in their bioactive state, has low thrombogenicity and can be robustly applied to medical devices, resisting delamination when deployed in vivo. Applying this process to attachment of proteins such as enzymes that inhibit thrombosis and anticoagulants such as heparin or heparin fragments, one can produce medical devices and other materials for use in vascular applications having a number of benefits including covalent attachment, not requiring intermediate linkers or chemistry; substrate independent—works on polymers, metals, ceramics, 3D shapes like stents, valves, etc.; bioactivity is retained; surface may retain greater bioactivity over time in vivo; Simultaneously supports endothelialization; can be stored for long periods, following freeze drying, and retains effectiveness when rehydrated and; surface is able to bind many fibrinolytic enzymes such as streptokinase, urokinase, tPA, plasmin).

Abstract: The present invention relates to an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide. An embolization particle of the invention for use in the treatment of cancer in combination with X-ray radiation or proton beam radiation, or use in embolization, is also described. The invention also relates to a process for producing an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide, which process comprises: (i) providing a microparticle; (ii) contacting the microparticle with a plurality of the nanoparticles; and (iii) heating the microparticle and the nanoparticles to form the embolization particle.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: The present invention relates generally to methods of preparing antimicrobial elastomeric articles that include an elastomeric article having an antimicrobial coating provided thereon. The antimicrobial elastomeric articles exhibit enhanced ability to reduce or eliminate microbes that come in contact with the article. Certain aspects of the invention are further directed to methods of packaging the antimicrobial elastomeric articles, where the packaged antimicrobial articles exhibit antimicrobial effectiveness for an extended period of time as compared to unpackaged antimicrobial articles. Antimicrobial elastomeric articles and packaged antimicrobial elastomeric articles prepared in accordance with the methods of the present invention are also provided.

Abstract: TPO was used to promote the growth of bone in both rats and in mice. Gaps in both mouse and in rat bones were treated with a scaffold sized to fit the gap. Scaffolds that included TPO promoted better outcomes than scaffolds that included BMP-2 or scaffolds that did not include either TPO or BMP-2. These data indicate that compounds that exhibit thrombopoietic activity such a recombinant TPO can be used to promote bone growth and healing in mammals.

Abstract: A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Abstract: The present disclosure relates to methods for stimulating collagen synthesis, cosmetic enhancement of soft tissue and/or inhibiting or treating scarring comprising administering a composition to an area to be treated within a soft tissue, wherein the composition comprises a tissue filler medium and a fluorophore; and illuminating the area with light having a wavelength which can be absorbed by the fluorophore.

Abstract: Disclosed herein is a block copolymer comprising a first block derived from a cyclo-alkyl vinyl monomer, a hydrogenated vinyl aromatic polymer or a hydrogenated vinyl pyridine polymers; and a second block derived from an acrylate monomer. Disclosed herein too is a method comprising reacting a first block derived from a cyclo-alkyl vinyl monomer, a hydrogenated vinyl aromatic polymer or a hydrogenated vinyl pyridine polymers with an initiator to form a macroinitiator; and polymerizing a second block onto the first block to form a block copolymer; where the second block is derived by polymerizing an acrylate monomer; and where the block copolymer has a chi parameter of greater than or equal to about 0.05, when measured at a temperature of 200° C. to 210° C.; where the chi parameter is a measure of interactions between the first block and the second block of the copolymer.

Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.